What’s Next in Pharmaceutical R&D? A Conversation with Upperton’s Director of Pharmaceutical Sciences
We speak to Upperton’s Director of Pharmaceutical Sciences, Laura Mason, about the upcoming trends she sees emerging in the R&D lab.
Does a One-Site CDMO Make a Difference in Drug Development?
A one-site CDMO is where GMP, R&D and manufacturing all operate on one site, making the movement of projects streamlined.
Tackling Poor Bioavailability with Early Formulation Strategies: eBook
Sniffing Out Solutions in the Nasal Drug Delivery Revolution
The nose to brain pathway can be leveraged to unlock new therapeutic possibilities. Learn about the opportunities of N2B delivery.
The Bright Side of Biologic Stability: A Thermofluor Screen for Rational Buffer Optimisation
Learn about the challenges of stabilising injectable biologics.
A Thermofluor Screen for the Rational Formulation of Injectable Therapeutic Protein Solutions
Upperton Pharma Solutions Awarded VaxHub Sustainable Grant to Advance Oral Vaccine Delivery in Partnership with the University of Oxford’s Pandemic Sciences Institute
Upperton will apply its expertise to enable the next generation of Adenovirus-vectored vaccines to be delivered without needles.
Product Considerations in Sterile Drug Formulation Development
Discover the critical product decisions in sterile drug formulation development. Learn how planning with your CDMO can streamline your path.
CTA Page
Talk to our experts Virtual Facility Tour Discover Upperton’s Oral Dosage Form Capabilities With capabilities covering tablets, powders in bottle/sachet, dry granulation, coated and uncoated tablets and capsules, you can be confident in our expertise in the development and manufacture of oral solid dosage forms. Learn More Discover Upperton’s Oral Dosage Form Capabilities Oral administration […]
Finished Dosage Forms vs. APIs: What’s the Difference in Pharmaceutical Manufacturing?
Explore the key differences between Finished Dosage Forms (FDFs) and APIs in drug development and manufacturing.